

Introducing Souvenaid

- A medical nutrition product clinically proven to improve memory in patients with early Alzheimer's disease^{5,6}
- Contains a unique, patented combination of nutrients designed to support synapse formation¹⁵
- Well tolerated with >90% product compliance^{5,6}

Recommend Souvenaid for your early AD patients



- ✓ To be taken once daily, every day
- ✓ Available in strawberry and vanilla flavours

NUTRICIA
Souvenaid

Find out more at www.Souvenaid.com

Souvenaid is a Food for Special Medical Purposes for the dietary management of early AD and must be used under medical supervision.

1. Terry RD, et al. Ann Neurol 1991;30:572-80. 2. Sperling, R. A., et al. Alzheimer's Dement 2011;7(3): 280-92. 3. Terry RD. J Geriatr Psychiatry Neurol 2006;19:125-8. 4. Scheff SW, et al. Neurobiol Aging 2006;27: 1372-1384. 5. Scheltens P, et al., Alzheimer's Dement. 2010 Jan;6(1):1-10.e1. 6. Scheltens P, et al. J Alzheimer's Dis. 2012;31: 225-236. 7. Kamphuis PJ, Scheltens P. J Alzheimer's Dis. 2010;20(3):765-75. 8. Glasa M, et al. J Nutr Health Aging. 2004;8:407-13. 9. Koseoglu E, Karaman Y. Clin Biochem. 2007;40:859-63. 10. Polidori MC, et al. Dement Geriatr Cogn Disord. 2004;18:265-70. 11. Conquer JA, et al. Lipids. 2000;35:1305-12. 12. Ravaglia G, et al. Am J Clin Nutr. 2004;80:483-8. 13. Corrigan FM, et al. Leukot Essent Fatty Acids. 1991;43:229-38. PubMed PMID: 1946550. 14. Corrigan FM, et al. Int J Biochem Cell Biol 1998; 30, 197-207. PubMed PMID: 9608673. 15. Sijben et al. DCL 2011;18:267-270.


Synapse
loss and
memory
in early
Alzheimer's
disease




NUTRICIA
Souvenaid

Synapse loss is one of the hallmarks of Alzheimer's disease

- Alzheimer's disease (AD) is characterised by beta amyloid plaques, neurofibrillary tangles and loss of synapses¹
- Synapse loss is believed to occur even before the onset of clinical symptoms of AD²



Synapse loss is the hallmark of AD that correlates best with impaired memory performance^{1,3,4}



Souvenaid has been shown to improve memory in early AD^{5,6}

- There is a strong body of literature supporting the belief that patients with AD have specific nutritional needs⁷⁻¹⁴

Souvenaid contains a unique, patented combination of nutrients designed to support synapse formation¹⁵

- Souvenaid significantly improved the primary efficacy endpoint of memory (memory domain of the NTB) over 24-weeks⁶

